DRR168527
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.470
- DNA_REPAIR+0.380
- WNT_BETA_CATENIN_SIGNALING+0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- P53_PATHWAY+0.330
- MYC_TARGETS_V1+0.320
- TGF_BETA_SIGNALING+0.310
- UV_RESPONSE_UP+0.280
- OXIDATIVE_PHOSPHORYLATION+0.260
- APOPTOSIS+0.250
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.430
- ALLOGRAFT_REJECTION-0.410
- INTERFERON_GAMMA_RESPONSE-0.370
- INFLAMMATORY_RESPONSE-0.340
- IL6_JAK_STAT3_SIGNALING-0.330
- COMPLEMENT-0.220
- KRAS_SIGNALING_UP-0.200
- SPERMATOGENESIS-0.180
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.140
- COAGULATION-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168575 | — | — | 0.839 |
| 2 | TCGA-22-5482-01A-01R-1635-07 | — | cohortSQ2 | 0.827 |
| 3 | SRR12475158 | — | — | 0.802 |
| 4 | SRR8942944 | — | — | 0.794 |
| 5 | R277 | — | — | 0.792 |
| 6 | TCGA-43-A474-01A-11R-A24H-07 | — | cohortSQ2 | 0.787 |
| 7 | TCGA-85-6798-01A-11R-1949-07 | — | cohortSQ2 | 0.783 |
| 8 | SRR6013542 | — | cohortSQ1 | 0.782 |
| 9 | s0112297 | — | — | 0.780 |
| 10 | BS_K3ER45RV | Med | Medulloblastoma | 0.780 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.380 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.330 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.280 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |